D.E. Shaw & Co
INFI

D.E. Shaw & Co’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

D.E. Shaw & Co’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36,133
Closed -$43K – 5275
2022
Q3 		$43K Sell
36,133
-759,054
-95% -$819K ﹤0.01% 4705
2022
Q2 		$502K Sell
795,187
-325,176
-29% -$250K ﹤0.01% 4085
2022
Q1 		$1.28M Sell
1,120,363
-464,097
-29% -$555K ﹤0.01% 3711
2021
Q4 		$3.56M Sell
1,584,460
-643,074
-29% -$1.61M ﹤0.01% 2769
2021
Q3 		$7.62M Buy
2,227,534
+2,119,509
+1,962% +$6.53M 0.01% 1723
2021
Q2 		$323K Buy
+108,025
New +$342K ﹤0.01% 4240
2019
Q2 		– Sell
-10,210
Closed -$19K – 3939
2019
Q1 		$19K Buy
+10,210
New +$14.9K ﹤0.01% 3541
2018
Q4 		– Sell
-19,745
Closed -$54K – 4067
2018
Q3 		$54K Buy
+19,745
New +$40.9K ﹤0.01% 3655
2017
Q4 		– Sell
-421,544
Closed -$561K – 3792
2017
Q3 		$561K Sell
421,544
-4,018
-0.9% -$4.99K ﹤0.01% 2842
2017
Q2 		$668K Buy
425,562
+229,098
+117% +$442K ﹤0.01% 2661
2017
Q1 		$634K Sell
196,464
-110,065
-36% -$271K ﹤0.01% 2603
2016
Q4 		$414K Buy
306,529
+62,762
+26% +$82K ﹤0.01% 2961
2016
Q3 		$381K Buy
243,767
+15,152
+7% +$23.3K ﹤0.01% 2927
2016
Q2 		$305K Sell
228,615
-143,841
-39% -$673K ﹤0.01% 3014
2016
Q1 		$1.96M Buy
372,456
+22,751
+7% +$139K ﹤0.01% 1884
2015
Q4 		$2.75M Buy
349,705
+99,399
+40% +$856K ﹤0.01% 1883
2015
Q3 		$2.12M Sell
250,306
-149,512
-37% -$1.38M ﹤0.01% 2054
2015
Q2 		$4.38M Sell
399,818
-73,758
-16% -$947K 0.01% 1567
2015
Q1 		$6.62M Buy
473,576
+95,103
+25% +$1.45M 0.01% 1210
2014
Q4 		$6.39M Sell
378,473
-100,134
-21% -$1.46M 0.01% 1386
2014
Q3 		$6.42M Buy
478,607
+111,544
+30% +$1.33M 0.01% 1402
2014
Q2 		$4.68M Buy
367,063
+200,724
+121% +$2.09M 0.01% 1679
2014
Q1 		$1.98M Sell
166,339
-6,125
-4% -$82.2K ﹤0.01% 2408
2013
Q4 		$2.38M Sell
172,464
-172,505
-50% -$2.44M ﹤0.01% 2352
2013
Q3 		$6.02M Sell
344,969
-287,784
-45% -$5.51M 0.01% 1428
2013
Q2 		$10.3M Buy
+632,753
New +$19.6M 0.02% 848

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

D.E. Shaw & Co's INFI Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2022, closing a stake of 36,133 shares — an estimated $43K sold.

D.E. Shaw & Co first reported a position in INFI in Q2 2013 and held it in 26 quarters. The position peaked at $10.3M in Q2 2013. 68 funds tracked by Wall St. Rank hold INFI as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 36,133 Infinity Pharmaceuticals, Inc. shares in Q4 2022, an estimated $43K.
  • D.E. Shaw & Co first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 26 quarters.
  • D.E. Shaw & Co's Infinity Pharmaceuticals, Inc. position peaked at $10.3M in Q2 2013.
  • 68 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.